Pharmacology

Michael W. Dryden, DVM, MS, PhD, DACVM (Parasitology), delivered a keynote address focused on canine heartworm disease on day 2 of the 2025 Fetch dvm360 Conference in Kansas City, Missouri.

The company voluntarily recalled its 2 lots of product due to potential health risks.

Regulatory approval from animal health authorities is still required before the vaccine can be made commercially available.

The JAK inhibitor will be available to veterinarians and dog owners in the United Kingdom by the end of Q3 2025.

Nostrum Laboratories cannot guarantee the safety of Sucralfate Tablets USP 1 gram manufactured after June 2023.

This latest approval builds on an earlier liquid formulation of generic methimazole for feline hyperthyroidism, which received FDA clearance earlier this month

Fluralaner for extended-release injectable suspension (Bravecto Quantum) is also indicated for treatment of lone star tick in dogs.

TruCan Ultra CIV H3N2/H3N8 will broadly protect canine patients from canine influenza.

The funding will support Gallant’s treatment for refractory feline chronic gingivostomatitis, which is in development.

Cefovecin Sodium for Injection is sponsored by Qilu Animal Health Products Co.

Kyle Bartholomew, DVM, DACVAA, discusses how combining treatment options can lead to improved outcomes.

Jeffrey N. Bryan, DVM, PhD, MS, DACVIM, discusses current methods and the need for advancement in how bone cancer is managed in dogs.

ELIAS Cancer Immunotherapy was combined with chemotherapy in a study with results presented at the 2025 ACVIM Forum.

Sirolimus delayed-release tablets (felycin-CA1; PRN Pharmacal) have conditional approval from the FDA.

Tatiana Henriques Ferreira, DVM, PhD, MSc, DACVAA, and Marlis Rezende, DVM, PhD, MSc, DACVAA, discuss which types of cases are ideal for inhalant anesthesia vs total intravenous anesthesia.

Elanco Animal Health’s ilunocitinib tablet (Zenrelia) was approved by the FDA in 2024.

Marlis Rezende, DVM, PhD, MSc, DACVAA, discusses the common conditions she sees in practice that best utilize TIVA for pain management.

The latest canine otitis externa medication is the only FDA-approved, 1-dose, in-clinic treatment for Pseudomonas aeruginosa and other pathogens.

Royal Canin is highlighting the importance of a personalized health plan based on each pets' unique needs with these products and designated day for awareness

Lee Pope, DVM, discusses dosage tips to share with pet owners in a dvm360 interview.

Dechra’s Otiserene is a single-dose, long-acting product that utilizes marbofloxacin

Visible particulate matter was observed in 2 products containing dexmedetomidine hydrochloride injection 0.5 mg/mL for dogs and cats.

The nutraceutical 4CYTE Epiitalis Forte Dog was previously only available abroad and is now distributed domestically by epiq Animal Health and Interpath Global.

OST-HER2 could be a frontline treatment for dogs and humans

The STAY study is investigating LOY-002, a therapy designed by Loyal to extend healthy lifespans in canines